skip to content
Pharmacoeconomic review report. Guselkumab (Tremfya) (Janssen Inc.). Preview this item
ClosePreview this item
Checking...

Pharmacoeconomic review report. Guselkumab (Tremfya) (Janssen Inc.).

Author: Canadian Agency for Drugs and Technologies in Health,
Publisher: Ottawa (ON) : CADTH, March 2018.
Series: Common drug review clinical review report.
Edition/Format:   eBook : Document : National government publication : English
Summary:
Guselkumab (Tremfya) is a fully human immunoglobulin G1 lambda (IgG1a) monoclonal antibody that binds selectively to the interleukin 23 (IL-23) protein with high specificity and affinity. Levels of IL-23 are elevated in the skin of patients with plaque psoriasis and guselkumab exerts its clinical effects in plaque psoriasis through blockade of the IL-23 cytokine pathway. The proposed indication submitted to Health  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Genre/Form: Table
Material Type: Document, Government publication, National government publication, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Canadian Agency for Drugs and Technologies in Health,
OCLC Number: 1084917829
Notes: "Version: Final."
Description: 1 online resource (1 PDF file (x pages)) : illustrations.
Series Title: Common drug review clinical review report.
Other Titles: Pharmacoeconomic review report for Tremfya
Guselkumab (Tremfya) (Janssen Inc.)

Abstract:

Guselkumab (Tremfya) is a fully human immunoglobulin G1 lambda (IgG1a) monoclonal antibody that binds selectively to the interleukin 23 (IL-23) protein with high specificity and affinity. Levels of IL-23 are elevated in the skin of patients with plaque psoriasis and guselkumab exerts its clinical effects in plaque psoriasis through blockade of the IL-23 cytokine pathway. The proposed indication submitted to Health Canada for guselkumab is for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The proposed recommended dose is 100 mg to be given as subcutaneous (SC) injection at week 0 and week 4, followed by maintenance dosing every eight weeks thereafter. The price is $3,060 per 100 mg/mL prefilled syringe.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/1084917829> # Pharmacoeconomic review report. Guselkumab (Tremfya) (Janssen Inc.).
    a schema:CreativeWork, schema:Book, schema:MediaObject ;
    library:oclcnum "1084917829" ;
    library:placeOfPublication <http://id.loc.gov/vocabulary/countries/onc> ;
    schema:about <http://experiment.worldcat.org/entity/work/data/8903077459#Topic/antibodies_monoclonal_therapeutic_use> ; # Antibodies, Monoclonal--therapeutic use
    schema:about <http://experiment.worldcat.org/entity/work/data/8903077459#Topic/cost_benefit_analysis> ; # Cost-Benefit Analysis
    schema:about <http://experiment.worldcat.org/entity/work/data/8903077459#Topic/antibodies_monoclonal_economics> ; # Antibodies, Monoclonal--economics
    schema:about <http://experiment.worldcat.org/entity/work/data/8903077459#Place/canada> ; # Canada.
    schema:about <http://experiment.worldcat.org/entity/work/data/8903077459#Topic/psoriasis_drug_therapy> ; # Psoriasis--drug therapy
    schema:alternateName "Guselkumab (Tremfya) (Janssen Inc.)" ;
    schema:alternateName "Pharmacoeconomic review report for Tremfya" ;
    schema:bookFormat schema:EBook ;
    schema:contributor <http://experiment.worldcat.org/entity/work/data/8903077459#Organization/canadian_agency_for_drugs_and_technologies_in_health> ; # Canadian Agency for Drugs and Technologies in Health,
    schema:datePublished "2018" ;
    schema:description "Guselkumab (Tremfya) is a fully human immunoglobulin G1 lambda (IgG1a) monoclonal antibody that binds selectively to the interleukin 23 (IL-23) protein with high specificity and affinity. Levels of IL-23 are elevated in the skin of patients with plaque psoriasis and guselkumab exerts its clinical effects in plaque psoriasis through blockade of the IL-23 cytokine pathway. The proposed indication submitted to Health Canada for guselkumab is for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The proposed recommended dose is 100 mg to be given as subcutaneous (SC) injection at week 0 and week 4, followed by maintenance dosing every eight weeks thereafter. The price is $3,060 per 100 mg/mL prefilled syringe."@en ;
    schema:exampleOfWork <http://worldcat.org/entity/work/id/8903077459> ;
    schema:genre "Government publication"@en ;
    schema:genre "Table"@en ;
    schema:genre "National government publication"@en ;
    schema:inLanguage "en" ;
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/8903077459#Series/cadth_common_drug_review> ; # CADTH common drug review
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/8903077459#Series/common_drug_review_clinical_review_report> ; # Common drug review clinical review report.
    schema:name "Pharmacoeconomic review report. Guselkumab (Tremfya) (Janssen Inc.)."@en ;
    schema:productID "1084917829" ;
    schema:url <http://www.ncbi.nlm.nih.gov/books/NBK533391/> ;
    wdrs:describedby <http://www.worldcat.org/title/-/oclc/1084917829> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/8903077459#Organization/canadian_agency_for_drugs_and_technologies_in_health> # Canadian Agency for Drugs and Technologies in Health,
    a schema:Organization ;
    schema:name "Canadian Agency for Drugs and Technologies in Health," ;
    .

<http://experiment.worldcat.org/entity/work/data/8903077459#Series/cadth_common_drug_review> # CADTH common drug review
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1084917829> ; # Pharmacoeconomic review report. Guselkumab (Tremfya) (Janssen Inc.).
    schema:name "CADTH common drug review" ;
    .

<http://experiment.worldcat.org/entity/work/data/8903077459#Series/common_drug_review_clinical_review_report> # Common drug review clinical review report.
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1084917829> ; # Pharmacoeconomic review report. Guselkumab (Tremfya) (Janssen Inc.).
    schema:name "Common drug review clinical review report." ;
    .

<http://experiment.worldcat.org/entity/work/data/8903077459#Topic/antibodies_monoclonal_economics> # Antibodies, Monoclonal--economics
    a schema:Intangible ;
    schema:name "Antibodies, Monoclonal--economics"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8903077459#Topic/antibodies_monoclonal_therapeutic_use> # Antibodies, Monoclonal--therapeutic use
    a schema:Intangible ;
    schema:name "Antibodies, Monoclonal--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8903077459#Topic/cost_benefit_analysis> # Cost-Benefit Analysis
    a schema:Intangible ;
    schema:name "Cost-Benefit Analysis"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8903077459#Topic/psoriasis_drug_therapy> # Psoriasis--drug therapy
    a schema:Intangible ;
    schema:name "Psoriasis--drug therapy"@en ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.